Axsome Therapeutics (NASDAQ:AXSM) posted its earnings results on Friday. The company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.02, MarketWatch Earnings reports.

NASDAQ:AXSM traded down $0.05 during mid-day trading on Friday, reaching $3.87. 448,120 shares of the company were exchanged, compared to its average volume of 336,109. Axsome Therapeutics has a 12 month low of $2.05 and a 12 month high of $5.95. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 0.74. The firm has a market cap of $102.91 million, a P/E ratio of -3.12 and a beta of -0.51.

Several equities research analysts have recently weighed in on AXSM shares. Zacks Investment Research lowered shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, September 12th. ValuEngine raised shares of Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. HC Wainwright set a $10.00 target price on shares of Axsome Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 9th. Finally, LADENBURG THALM/SH SH set a $5.00 target price on shares of Axsome Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 17th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Axsome Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $10.10.

An institutional investor recently raised its position in Axsome Therapeutics stock. Alethea Capital Management LLC boosted its stake in shares of Axsome Therapeutics Inc (NASDAQ:AXSM) by 132.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 270,823 shares of the company’s stock after acquiring an additional 154,323 shares during the quarter. Axsome Therapeutics makes up approximately 1.5% of Alethea Capital Management LLC’s holdings, making the stock its 12th biggest holding. Alethea Capital Management LLC owned about 1.05% of Axsome Therapeutics worth $867,000 as of its most recent SEC filing. 16.70% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Axsome Therapeutics (AXSM) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/11/10/axsome-therapeutics-axsm-posts-quarterly-earnings-results-beats-expectations-by-0-02-eps.html.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

See Also: Google Finance Portfolio Workaround

Earnings History for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.